Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12826264 | 0.82 | — | — | |
| SCHEMBL15782488 | 0.76 | HTR2C (0.35) | HTR2C | |
| SCHEMBL19221587 | 0.76 | — | — | |
| SCHEMBL15782474 | 0.76 | HTR2C (0.35) | HTR2C | |
| SCHEMBL20858817 | 0.74 | HTR2C (0.34) | HTR2C | |
| SCHEMBL17113871 | 0.73 | KMT2A (0.33) | KMT2AMEN1PAX8 | |
| SCHEMBL11593411 | 0.71 | — | — | |
| SCHEMBL10831129 | 0.71 | — | — | |
| SCHEMBL21648701 | 0.69 | HTR2C (0.32) | HTR2C | |
| SCHEMBL20705654 | 0.69 | HTR2C (0.41) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192619-A1 | Processes for the Preparation of a Kinase Inhibitor | EXELIXIS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-11414396-B2 | Process for making compounds for use in the treatment of cancer | EXELIXIS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20200392104-A1 | Novel Process for Making Compounds for Use in the Treatment of Cancer | EXELIXIS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10793541-B2 | Process for making compounds for use in the treatment of cancer | EXELIXIS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10736886-B2 | Methods of using c-Met modulators | EXELIXIS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190185447-A1 | NOVEL PROCESS FOR MAKING COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-20190151302-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-9771347-B2 | Process for making compounds for use in the treatment of cancer | EXELIXIS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170042880-A1 | Method of Treating Lung Adenocarcinoma | EXELIXIS, INC. | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414396-B2 | Process for making compounds for use in the treatment of cancer | BRAF, MAP3K19, MAP3K1 | HTR2C 4639/4885KMT2A 2338/4885MEN1 739/4885 |
| US-20200392104-A1 | Novel Process for Making Compounds for Use in the Treatment of Cancer | MAP3K19, BRAF, MAP3K20 | HTR2C 4668/4885KMT2A 3257/4885MEN1 1156/4885 |
| US-20170042880-A1 | Method of Treating Lung Adenocarcinoma | ROS1, SLC67A1, MET | HTR2C 3641/4885KMT2A 1015/4885MEN1 1179/4885 |
| US-10793541-B2 | Process for making compounds for use in the treatment of cancer | BRAF, MAP3K19, MAP3K1 | HTR2C 4639/4885KMT2A 2338/4885MEN1 739/4885 |
| US-20190185447-A1 | NOVEL PROCESS FOR MAKING COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | MAP3K19, BRAF, MAP3K20 | HTR2C 4668/4885KMT2A 3257/4885MEN1 1156/4885 |
| US-10736886-B2 | Methods of using c-Met modulators | MET, KRAS, HGF | HTR2C 834/4885KMT2A 1294/4885MEN1 32/4885 |
| US-20190151302-A1 | Methods of Using C-Met Modulators | MET, KRAS, HGF | HTR2C 834/4885KMT2A 1294/4885MEN1 32/4885 |
| US-20230192619-A1 | Processes for the Preparation of a Kinase Inhibitor | MET, HGF, BRAF | HTR2C 2819/4885KMT2A 853/4885MEN1 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.